Deubiquitinase (DUB) enzymes have emerged as an exciting class of new drug targets that are implicated in a wide range of different disease states.
Modulation of DUB function by DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs), and Deubiquitinase-Targeting Chimeras (DUBTACs), opens up new opportunities for the development of novel therapeutics. Though largely untapped for this purpose, DUBs and the discovery of DUB modulators is now gaining pace in the continued pursuit to drug the undruggable.
Ubiquigent™ is developing an internal asset pipeline across core therapeutic areas, with active programmes to develop DUB inhibitors, DUB-targeting PROTACs and DUBTACs. We will continue to develop our pipeline in-house as well as explore the potential to progress our assets through partnerships with pharma, biotech, and academic-based collaborators.
